Novacyt SA
NCYT
Company Profile
Business description
Novacyt SA is engaged in developing and selling diagnostic products for cancer and infectious diseases. The company operates its business through the following business segments: Primer Design, IT-IS International, Lab21 Products, Corporate, Yourgene Health and Intercompany eliminations. Majority of the revenue is generated from Yourgene Health segment.
Contact
131 Boulevard Carnot
Le Vesinet78110
FRASector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
234
Stocks News & Analysis
stocks
Tesla’s stock is in trouble, but this fund manager sees a comeback in 2026
Tesla’s challenges echo past issues the company has overcome, says Zevenbergen’s Joe Dennison.
stocks
Cheap ASX energy play boasts strong cash flows and balance sheet
Markets appear overly bearish on the company despite the company having attracting growth options.
stocks
Market overreacts to earnings miss from moated ASX retailer
Our forecast recovery is off to a slow start but the sell-off appears to have gone too far.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,245.00 | 66.30 | -0.71% |
| CAC 40 | 7,843.04 | 126.65 | -1.59% |
| DAX 40 | 24,273.12 | 89.97 | -0.37% |
| Dow JONES (US) | 45,317.87 | 313.87 | -0.69% |
| FTSE 100 | 9,321.40 | 12.20 | 0.13% |
| HKSE | 25,829.91 | 490.77 | 1.94% |
| NASDAQ | 21,510.98 | 14.45 | 0.07% |
| Nikkei 225 | 42,807.82 | 174.53 | 0.41% |
| NZX 50 Index | 13,079.50 | 36.74 | 0.28% |
| S&P 500 | 6,451.27 | 15.64 | -0.24% |
| S&P/ASX 200 | 8,972.40 | 71.70 | -0.79% |
| SSE Composite Index | 3,883.56 | 57.80 | 1.51% |